COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Zixin Pharmaceuticals behind the "203 Resolutions"
“I would like to thank the National Standards Committee and the Chinese Medicine Administration for their trust in Zixin Pharmaceuticals, giving us such an opportunity to contribute to the international standardization of Chinese medicine; I would also like to thank the ISO organization for providing the best for the standardization of Chinese medicine. Platform."
As the sole authorized support unit of the domestic pharmaceutical enterprise conference, Guo Chunlin, chairman and general manager of Jilin Zixin Pharmaceutical Co., Ltd., expresses gratitude behind it, is the International Organization for Standardization/Chinese Medicine held in Beijing from June 1st to 4th. (tentative name) Technical Committee (ISO/TC249) The two major decisions at the closing ceremony of the sixth plenary meeting: First, cancel the "tentative name"; second, the Zixin Pharmaceutical in the standardization of Chinese medicine Contributions were written into the 203 resolutions of the General Assembly.
For the cancellation of the "provisional name", the industry's interpretation is: ISO/TC249 is established to promote the healthy development of traditional medicine represented by traditional Chinese medicine in the world through standardized channels. This official naming makes the world More people share Chinese medicine resources, which is a milestone in promoting the standardization of Chinese medicine and accelerating the internationalization of Chinese medicine. From a certain perspective, this formal naming is to confirm the status of the Chinese traditional Chinese medicine.
“Thank you for your contribution to the company in the form of resolutions, and for the first time at the international conference!” Wang Guoqiang, deputy director of the National Health and Family Planning Commission and director of the State Administration of Traditional Chinese Medicine, explained: Zixin Pharmaceutical actively participates in ISO/TC249 proprietary Chinese medicine. The research and formulation of international standards has enabled China's proprietary Chinese medicines to go abroad, participate in international competition, better serve the health of all mankind, establish the status of a sovereign state of Chinese medicine, and also make a strategic vision for the implementation of China's “One Belt, One Road” strategy. Deserved contribution.
As we all know, the standardization work of Chinese medicine is "the trend of the trend, the general trend", what kind of signals are the two heavy news messages? What kind of contribution has Jilin Zixin made in order to win this honor?
Cancel "tentative name"
In today's world, whoever masters the right to formulate standards, has mastered the initiative of technology and economic competition to a certain extent. With the huge medical value and market potential of traditional medicine, Chinese medicine has rapidly spread in more and more countries and regions, and the international voice and demand for TCM standardization are increasing.
In this regard, the understanding of Guo Chunlin, chairman and general manager of Jilin Zixin Pharmaceutical Co., Ltd., is that Japan, South Korea, Europe and the United States have carried out research and formulation of traditional medical standards, and strived for the development of international standards through various forms and channels. right. In a certain sense, whether it is "autonomous" or "dependent" in the formulation of international standards determines the future and destiny of the international development of Chinese medicine.
It is understood that in 2009, the International Organization for Standardization/Traditional Chinese Medicine Technical Committee (ISO/TC249) was formally established to establish a new pattern of TCM standardization. So far, the world's largest and most authoritative international standards organization has developed an international standard development platform tailored for Chinese medicine.
In the past five years, China has become the leader in the development of Chinese medicine standards with the largest number of ISO Chinese medicine standard project proposals and the largest number of experts, further expanding the influence of Chinese medicine in the world.
The sixth plenary meeting of ISO/TC249 was held in Beijing, China from June 1st to 4th, 2015. The conference was attended by 12 member states including China, Australia, Canada, Germany, Japan, South Korea and ISO headquarters, the World Federation of Acupuncture Associations, the World Federation of Chinese Medicine Societies, and ISO/TC215. It is the most in history. The Chinese representative is composed of 138 experts from 17 provinces, municipalities, autonomous regions and Hong Kong and Macao Special Administrative Regions.
The International Organization for Standardization/Traditional Chinese Medicine (Tentative Name) Technical Committee (ISO/TC249) canceled the 'tentative name', which was the first heavy news at the closing ceremony of the sixth plenary session of ISO/TC249.
"The closing ceremony decided to cancel the 'tentative name'. On the surface, there are only three words missing, but the gold content is very high." Guo Chunlin, chairman and general manager of Jilin Zixin Pharmaceutical Co., Ltd., believes that this is the international standardization authority. The full affirmation of the achievements of the standardization of traditional Chinese medicine indicates that China has begun to grasp the leading power of international standardization of Chinese medicine, laying a solid foundation for establishing the status of the sovereign state of Chinese medicine, and will face more opportunities in the fierce international competition.
Article 203 resolution
The contribution of Jilin Zixin Pharmaceutical in the standardization of traditional Chinese medicine was written into the resolution of the General Assembly. This is the second heavy news at the sixth plenary meeting of ISO/TC249.
The translated contents of the 203 resolutions are as follows: The International Organization for Standardization of Traditional Chinese Medicine Technical Committee (ISO/TC249) to the National Standardization Administration Committee, the State Administration of Traditional Chinese Medicine, all volunteers and Zixin Pharmaceuticals and other units for the successful completion of this Beijing Conference I would like to express my sincere gratitude for the contribution.
“Thank you for your contribution to the company in the form of resolutions, and for the first time at the international conference!” An industry authority believes that 203 resolutions have enabled Zixin Pharmaceutical to gain international recognition and its image is deeply rooted in the hearts of member states. Standard bedding foundation.
What kind of contribution has Jilin Zixin Pharmaceutical made in order to win such a privilege? Under various speculations, Guo Chunlin, Chairman and General Manager of Jilin Zixin Pharmaceutical Co., Ltd. gave the standard answer: Jilin Zixin Pharmaceutical Co., Ltd. as the only outstanding pharmaceutical company in China became the only authorized support unit of the conference. Before this, Jilin Zi Xin Pharmaceutical has participated in 4 ISO/TC249 meetings and has been committed to promoting the international standardization of Chinese medicine.
It is understood that Jilin Zixin Pharmaceutical Co., Ltd. was established in May 1998. It is a pillar of the three major industries of Chinese patent medicine, ginseng industry and gene sequencer in Jilin Province. It integrates scientific research, production, sales and Chinese herbal medicine. High-tech joint-stock enterprises. The company was listed on the Shenzhen Stock Exchange in March 2007 with the stock code “002118”. Since entering the ginseng industry, the company has actively participated in the formulation of ginseng standardization at different levels, such as international, national, industry and local. It has participated in the formulation of 4 local standards for ginseng food in Jilin Province, 38 enterprise standards, and 4 ginseng health food enterprise standards. . In 2012, Zixin Pharmaceutical participated in the third plenary meeting of ISO/TC249 and actively participated in the formulation of the international standard for ISO "Chinese medicine - ginseng seed seedlings - Part 1: Asian ginseng". This standard was in 2014. It was published by ISO in the first half of the year and became one of the first international standards for Chinese medicine published by ISO.
In May 2014, Zixin Pharmaceutical participated in the fifth plenary meeting of ISO/TC249 and actively participated in the formulation of the requirements of the production process of red ginseng industry. At this conference, Zixin Pharmaceutical submitted a proposal to the State Administration of Traditional Chinese Medicine and the Chinese delegation of ISO/TC249 to fully support the Sixth Plenary Meeting. The Chinese delegation submitted an application to the General Assembly and was approved by the General Assembly.
In this regard, Guo Chunlin, chairman and general manager of Jilin Zixin Pharmaceutical Co., Ltd., said that the world's countries have been integrated into highly developed information and trade. Economic globalization and market integration have become the trend of the times. The bridges and ties that play a role between countries and regions are technical standardization. The international standard of Chinese medicine is the fundamental guarantee for providing safe, effective and quality-controlled Chinese medicine products and services, and is a necessary condition for expanding the trade of Chinese medicine products and services.
More than just "likes"
Industrial technology standards are the commanding heights of industrial development and are at the highest end of the entire value chain. Therefore, mastering relevant standards has become an extension of national sovereignty in the economic category.
When South Korea proposed the standard of red ginseng, Jilin Zixin Pharmaceutical realized that it could no longer "silence". With the steady growth of pharmaceutical production and sales, the ginseng industry is booming, and the sequencing of genes is in full swing, Jilin Zixin Pharmaceutical is actively investing in the standard brake work of ginseng – for China to win a better international discourse and develop for the national industry. Adding assistance has become the persistence and belief of Zixin Pharmaceutical's standardization work.
The pointer of time jumped In 2010, Jilin Zixin Pharmaceutical adjusted its industrial structure, entered the ginseng industry, and took the ginseng industry as the vanguard of the company's future development. He held the banner of “Technology Ginseng” and became the promoter of the development of ginseng industry in Jilin Province. In April 2010, the Chinese ginseng genome project was officially launched, marking the official launch and full implementation of ginseng genome research and development. In November of the same year, Zixin Pharmaceutical and the Tonghua Municipal Government, the Changchun Branch of the Chinese Academy of Sciences, and the Beijing Genomics Institute of the Chinese Academy of Sciences signed a strategic cooperation framework agreement for ginseng industry, officially launching the ginseng genome project.
In August 2014, the Chinese Medicine Resource Center of China Academy of Chinese Medical Sciences, together with 6 family members and nearly 10 research institutes, established the “Ginseng International Standard Technology Alliance” and actively participated in the research and formulation of ginseng international standards; He served as the first executive director unit and assumed the work of the alliance secretariat. In 2015, Zixin Pharmaceutical Co., Ltd. undertook the construction of the Secretariat of the International Standards and Technology Alliance of Ginseng. The location is located in Beijing and has been actively carrying out various related work.
In the eyes of the 12 member states and ISO headquarters, the World Federation of Acupuncture Associations, the World Federation of Chinese Medicine Associations, ISO/TC215, etc., Jilin Zixin Pharmaceutical is undoubtedly the most shining "star".
During the break of the meeting, delegates or around the exhibition board of Jilin Zixin Pharmaceutical, understand the development of Chinese medicine industry in China, understand the industrialization of Jilin Zixin Pharmaceutical; or stand in front of the booth of Jilin Zixin Pharmaceutical. Directly experience the ginseng products of Jilin Zixin Pharmaceutical Co., Ltd., Zixinhong, fresh ginseng honey tablets, jade red face, red ginseng gelatin cake, ginseng, ginseng binaural beverage, ginseng enzyme fruit tree fermented beverage, etc., frequently obtained by participants Recognition and praise.
Jilin Zixin won more than just “likes” at this meeting. During the meeting, a Dutch academician visited Zixin Pharmaceutical to clearly express their demand for the ginseng industry. For example, ginseng has a good hangover and liver protection effect, and they are all interested.
"Ginseng is an important part of traditional Chinese medicine, and the formulation of relevant international standards is crucial to the development of ginseng industry. Using ISO/TC249 platform, actively participate in the research and development of international standards for ginseng and its products, so that the world can enjoy China's high The quality of ginseng is the mission of Zixin Pharmaceutical. “Guo Chunlin, Chairman and General Manager of Jilin Zixin Pharmaceutical Co., Ltd., speaks the goal of Zixin Pharmaceutical.
The goal is important and the action is more important. At present, Zixin Pharmaceutical has made a census on the ginseng industry in China for 3 months.
In the next step, Zixin Pharmaceutical will continue to conduct a thorough survey and research on the ginseng industry nationwide, using ginseng genome maps and other internationally advanced means to breed seedlings for ginseng varieties and restore artificial ginseng to restore wild ginseng. The traits and efficacy, on the basis of the use of high-end biological information, make it better suited for drug research and development, and lay a solid foundation for the leading position of Chinese medicine international standardization and the establishment of the status of Chinese medicine.